Euro

HSTS

DNSSEC

Google Maps

IPv6

reCAPTCHA v2

Microsoft

PostalAddress Schema

COVID-19

Google Maps Embed

Chief Executive Officer

David Gonzalez Angulo

General Counsel

Scott Sukenick

Founder

Silvia Helou

Vice President, Regulatory Affairs and Quality Assurance

Glen Park

Vice President Clinical Development and Medical Affairs

Nkechi Azie

Vice President, Pharmaceutical Development

Rajeshwar Motheram

VP, Business Development & Alliance Management

Rossana Ferrara-Pontoriero

Business Management

Astra Sparks

Engineering

Bob Rodebaugh

Associate Director Clinical Operations

Christopher Anastasi

Kent Gossett

Ann F. Hanham

Ed Penhoet

Mounia Chaoui

Charles F. Osborne

Chief Financial Officer

Christine Coyne

Chief Commercial Officer

Jim Maffezzoli

Vice President Marketing & Sales

David Angulo

Chief Medical Officer

Ivor Macleod

Eric Francois

Marco Taglietti

President and Chief Executive Officer

Health Care Companies With Less Than $500M in Revenue (Top 10K)

North Carolina Companies With Less Than $1B in Revenue (Top 10K)

Pharmaceutical Public Companies With Fewer Than 1000 Employees

Southern US Companies With Fewer Than 1000 Employees (Top 10K)

SCYNEXIS, Inc. operates as a drug discovery and development company in the United States and internationally. It engages in drug discovery, development, and manufacturing projects in various areas, such as antibacterials, antifungals, antiparasitics, antivirals, carbohydrates, central nervous system, controlled substances, kinases, natural products, neglected diseases, nuclear hormones, nucleosides, oncology, ophthalmology, pain, and prodrugs. The company offers SCY-635, a drug that is used for patients who are chronically infected with genotype 1 hepatitis C virus. It also provides contract research solutions, including medicinal chemistry, discovery biology, ADMET-PK, bioanalysis and analytical chemistry, process chemistry, and cGMP manufacturing. The company delivers drug pipeline solutions to pharmaceutical, health, and life science partners. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is based in Durham, North Carolina.

Post-IPO Equity - SCYNEXIS

Hercules Capital

Silicon Valley Bank

Post-IPO Debt - SCYNEXIS

Debt Financing - SCYNEXIS

Venture Round - SCYNEXIS

Durham

North Carolina

United States

North America

SCYNEXIS

SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Scynexis reports Q2 EPS (30c), consensus (20c)

SCYNEXIS secures $10 million milestone from GSK

SCYNEXIS shareholders approve key proposals at annual meeting By Investing.com

Scynexis: Update Following Restructuring Of GSK Deal (NASDAQ:SCYX)

SCYNEXIS Inc reports results for the quarter ended in December - Earnings Summary

SCYNEXIS to Participate in Guggenheim’s 6th Annual Biotechnology Conference

Scynexis' candidate demonstrates efficacy in mucormycosis mouse model

A novel class of glucan synthase inhibitor antifungal with broad spectrum activity, suitable for oral and IV use, targeting serious fungal infections including resistant strains.

A second-generation triterpenoid with broad-spectrum antifungal activity, showing promise against difficult to treat and emerging fungal infections.

A clinical trial investigating ibrexafungerp as an oral step-down therapy following IV echinocandin for invasive candidiasis and candidemia.

Focuses on addressing the unmet need in women’s health for the treatment of vaginal yeast infections.

Targets the treatment of women suffering from recurrent episodes of vulvovaginal candidiasis.

India

Asia

Pakistan

HTML5

Amazon EC2

F5 NGINX

Vimeo

Google Fonts

Apache Server

Bootstrap

Comodo PositiveSSL Certificates

Fonts.com

Office 365

SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

SCYNEXIS, Inc.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Mar 8, 2024 6:36 PM	02a2f721
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 8, 2024 6:36 PM	b4fb7467
company summary	general
signals	general
crunchbase trigger	general	Nov 22, 2024 7:44 AM	f9fcee08
crunchbase profile	general	Nov 22, 2024 9:33 AM	1d67ba1d
li profile	general
translate crunchbase fundingrounds	general	Nov 22, 2024 2:05 PM	b0e859a6
peers	general
news basic	general	Mar 8, 2024 6:36 PM	c17ff180
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:SCYNEXIS

SCYNEXIS, Inc.

Last Close

1.19

22/11 21:00

Market Cap

74.43M

Beta: -

Volume Today

148.07K

Avg: -